Literature DB >> 20624692

Bioactive glass S53P4 as bone graft substitute in treatment of osteomyelitis.

N C Lindfors1, P Hyvönen, M Nyyssönen, M Kirjavainen, J Kankare, E Gullichsen, J Salo.   

Abstract

Bioactive glass (BAG)-S53P4 is an osteoconductive bone substitute with proven antibacterial and bone bonding properties. In a multicentre study 11 patients with verified chronic osteomyelitis in the lower extremity and the spine were treated with BAG-S53P4 as a bone substitute. The cavitary bone defect and the surrounding of a spinal implant were filled with BAG-S53P4. The most common pathogen causing the infection was Staphylococcus aureus. The mean follow-up was 24 months (range 10-38). BAG-S53P4 was well tolerated. Nine patients healed without complications. One patient who achieved good bone formation sustained a superficial wound infection due to vascular problems in the muscle flap, and one patient had an infection due to a deep haematoma. This study shows that BAG-S53P4 is a good and well-tolerated bone substitute, and can be used in treatment of osteomyelitis with good primary results.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20624692     DOI: 10.1016/j.bone.2010.05.030

Source DB:  PubMed          Journal:  Bone        ISSN: 1873-2763            Impact factor:   4.398


  34 in total

1.  The influence of SrO and CaO in silicate and phosphate bioactive glasses on human gingival fibroblasts.

Authors:  J Massera; A Kokkari; T Närhi; L Hupa
Journal:  J Mater Sci Mater Med       Date:  2015-06-23       Impact factor: 3.896

2.  Bioactive glass as dead space management following debridement of type 3 chronic osteomyelitis.

Authors:  Willem Oosthuysen; Rudolph Venter; Yashwant Tanwar; Nando Ferreira
Journal:  Int Orthop       Date:  2019-11-08       Impact factor: 3.075

3.  Bioactive glass granules for mastoid and epitympanic surgical obliteration: CT and MRI appearance.

Authors:  Daniele Bernardeschi; Bruno Law-Ye; Franck Bielle; Baptiste Hochet; Olivier Sterkers; Didier Dormont; Nadya Pyatigorskaya
Journal:  Eur Radiol       Date:  2019-03-19       Impact factor: 5.315

4.  Through the looking glass; bioactive glass S53P4 (BonAlive®) in the treatment of chronic osteomyelitis.

Authors:  J McAndrew; C Efrimescu; E Sheehan; D Niall
Journal:  Ir J Med Sci       Date:  2013-01-05       Impact factor: 1.568

5.  Enhanced osteoconductivity of polyethersulphone nanofibres loaded with bioactive glass nanoparticles in in vitro and in vivo models.

Authors:  A Ardeshirylajimi; S Farhadian; F Jamshidi Adegani; S Mirzaei; M Soufi Zomorrod; L Langroudi; A Doostmohammadi; E Seyedjafari; M Soleimani
Journal:  Cell Prolif       Date:  2015-06-29       Impact factor: 6.831

6.  Bioactive glass granules: a suitable bone substitute material in the operative treatment of depressed lateral tibial plateau fractures: a prospective, randomized 1 year follow-up study.

Authors:  Jouni T Heikkilä; Juha Kukkonen; Allan J Aho; Susanna Moisander; Timo Kyyrönen; Kimmo Mattila
Journal:  J Mater Sci Mater Med       Date:  2011-03-23       Impact factor: 3.896

7.  Enchondromas of the Hand: Curettage With Autogenous Bone vs. Bioactive Glass S53P4 for Void Augmentation.

Authors:  Nina Lindfors; Elias Kukkonen; Antti Stenroos; Panu H Nordback; Turkka Anttila; Samuli Aspinen
Journal:  In Vivo       Date:  2022 May-Jun       Impact factor: 2.406

8.  In Situ Gelling Hydrogel with Anti-Bacterial Activity and Bone Healing Property for Treatment of Osteomyelitis.

Authors:  Sun Woo Jung; Se Heang Oh; In Soo Lee; June-Ho Byun; Jin Ho Lee
Journal:  Tissue Eng Regen Med       Date:  2019-08-22       Impact factor: 4.169

9.  Bioactive glass S53P4 vs. autologous bone graft for filling defects in patients with chronic osteomyelitis and infected non-unions - a single center experience.

Authors:  Eva Steinhausen; Rolf Lefering; Martin Glombitza; Nikolaus Brinkmann; Carsten Vogel; Bastian Mester; Marcel Dudda
Journal:  J Bone Jt Infect       Date:  2021-01-12

10.  Effect of S53P4 bioactive glass and low-level laser therapy on calvarial bone repair in rats submitted to zoledronic acid therapy.

Authors:  Caio Peres Bellato; Danilo Louzada de Oliveira; Marcus Vinicius Satoru Kasaya; David Moreira; Marcelo Augusto Cini; Patricia Pinto Saraiva; Jéssica Lemos Gulinelli; Pâmela Leticia Santos
Journal:  Acta Cir Bras       Date:  2021-07-09       Impact factor: 1.388

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.